Therapy for multiple sclerosis with interferonβ-1b. Advice to patients, including how to deal with side effects;Therapie der multiplen sklerose mit interferon-β-1b. Aufklärung des patienten und umgang mit nebenwirkungen

Nervenarzt

Volumn 67, Issue 6, 1996, Pages 452-456

  Walther, E U ^a   Dietrich, E ^b   Hohlfeld, R ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Max Planck Institut   (Germany)

Author keywords

Interferon ; Multiple sclerosis; Side effects; Therapy

Indexed keywords

BETA INTERFERON; ETHACRIDINE LACTATE; HYDROCORTISONE; IBUPROFEN; INTERFERON BETA SERINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

HUMAN; INFLUENZA; INJECTION PAIN; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; SHORT SURVEY; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; BLOOD CELL COUNT; FEMALE; HUMANS; INTERFERON-BETA; LIVER FUNCTION TESTS; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PATIENT EDUCATION; RECOMBINANT PROTEINS;

EID: 0029937155     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Betaseron® (Interferon beta-1b), amerikanische Packungsbeilage. Berlex Laboratories, Juli 1993, Richmond, CA
2. Camenga DL, Johnson KP, Alter M, Engelhardt CD, Fishman PS, Greenstein JI, Haley AS, Hirsch RL, Kleiner JE, Kofie VY, Koskie CL, Margulies SL, Panitch HS, Valero R (1986) Systemic recombinant α-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 43: 1239-1246
3. Grant I (1986) Neuropsychological and psychiatric disturbances in multiple sclerosis. In: McDonald WI, Silberberg DH (eds) Multiple sclerosis. Butterworths, pp 134-152
4. Hartung HP, Hohlfeld R (1994) Interferon-β zur Behandlung der schubförmig verlaufenden Multiplen Sklerose. Nervenarzt 65: 139-145
5. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z (1987) Mood disorders and multiple sclerosis. Arch Neurol 44: 376-378
6. Johnson KP, Costello K, Kalz E, Snyder DH (1994) Managing subcutaneously self-injected therapy for multiple sclerosis. Advanced Therapeutics Communications, Secaurus, NJ
7. Knobler RL, Kelley CL, Trantas F, Webster GF, Lublin FD (1994) Interferon beta-lb induced ulcerative skin lesions in MS [abstract]. J Neuroimmunol 54:173
8. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452
9. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS (1996) Management of patients recieving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 46: 12-18
10. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group (1993) Interferon beta1b is effective in relapsing-rernitting multiple sclerosis. II. MR1 analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662-667
11. Rao SM (1986) Neuropsychology of multiple sclerosis. J Clin Exp Neuropsychology 8: 503-542
12. Sadovnick AD, Eisen K, Ebers GC Paty DW (1991) Cause of death in patients attending multiple sclerosis clinics. Neurology 41: 1193-1196
13. Sheremata WA, Taylor JR, Elgart GW (1995) Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med 332: 1584
14. Stenager EN, Stenager E, Koch-Henriksen N, Bronnum-Hansen H, Hyllested K, Jensen K, Bille-Brahe U (1992) Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 55: 542-545
15. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43: 655-661
16. The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45: 1277-1285